Biotech Values

[DewDiligence]

DNDN: How can Miller make statements about [Provenge] profit margins without knowing how much dndn plans to charge/be reimbursed?

Miler’s main point is that Provenge will have a lower gross margin than a typical biopharmaceutical. We won’t know how much lower until we know the price, but I think it’s clear that Provenge’s gross margin will be on the low side at any conceivable pricing level.